About this Research Topic
Inflammasomes are multimeric protein complexes activated in response to a wide range of pathogens and damage-associated molecular patterns that induce auto-processing of the proenzyme caspase-1. Activation of caspase-1 further results in pyroptotic cell death, and processing and release of the inflammatory cytokines, IL1b and IL18. A diverse range of sensors, triggers, and regulators makes inflammasome activation a tightly controlled process that is central to health and disease. Dysregulation of these processes are associated with various inflammatory disorders, including sepsis, cancer, cardiovascular diseases and even neurological disorders.
The aim of this Research Topic is to highlight recent advances in the regulation and function of inflammasome and associated molecules in modulating immunity.
Areas to cover may include:
• The regulation and consequences of inflammasome activation;
• The role of Inflammasomes during infections, cancer, and immunotherapy;
• Lessons from inflammasome associated autoinflammatory disorders;
• Intersection with other forms of cell death;
• Delinking the outcomes of inflammasome activation- cell death, cell rupture and cytokine release;
• Biologics that target inflammasomes: Harnessing biological information for feasible therapies.
F. Ghiringhelli received speaker honoraria from Lilly, Sanofi, BMS, Astra Zeneca and Amgen, received funding for clinical trials from Astra Zeneca, received travel grants from Roche France, Amgen and Servier, and is an advisory board member for Merck Serano, Amgen, Roche France and Sanofi.
The aim of this Research Topic is to highlight recent advances in the regulation and function of inflammasome and associated molecules in modulating immunity.
Areas to cover may include:
• The regulation and consequences of inflammasome activation;
• The role of Inflammasomes during infections, cancer, and immunotherapy;
• Lessons from inflammasome associated autoinflammatory disorders;
• Intersection with other forms of cell death;
• Delinking the outcomes of inflammasome activation- cell death, cell rupture and cytokine release;
• Biologics that target inflammasomes: Harnessing biological information for feasible therapies.
F. Ghiringhelli received speaker honoraria from Lilly, Sanofi, BMS, Astra Zeneca and Amgen, received funding for clinical trials from Astra Zeneca, received travel grants from Roche France, Amgen and Servier, and is an advisory board member for Merck Serano, Amgen, Roche France and Sanofi.
Keywords: inflammasome, inflammatory cell death
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
